Overview

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

Status:
Completed
Trial end date:
2021-08-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Incyte Corporation